Evelo Biosciences, Inc. (EVLO)

USD 0.0

(0.0%)

Market Cap (In USD)

9491.00

Revenue (In USD)

-

Net Income (In USD)

-114.52 Million

Avg. Volume

3964.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.1
PE
-
EPS
-
Beta Value
1.304
ISIN
US2997342025
CUSIP
299734103
CIK
1694665
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Craig R. Jalbert CIRA
Employee Count
-
Website
https://www.evelobio.com
Ipo Date
2018-05-08
Details
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.